Acute esophageal toxicity (AET) is a common complication and dose-limiting toxicity in thoracic radiotherapy. Previous studies demonstrated several clinical and dosimetric parameters of AET in patients with lung cancer. However, there are few reports dealing with these variables in intra-thoracic malignancies, including lung cancer and other thoracic malignancy. The purpose of this study was to evaluate the clinical and dosimetric factors associated with AET in patients with intra-thoracic malignancies. We examined 61 patients with intra-thoracic malignancies treated with radiotherapy: 34 patients with non-small-cell lung cancer (55%), 9 cases with small-cell lung cancer (15%), 7 cases with thymic cancer (11%), 4 thymomas (7%), 2 malignant lymphomas (3%), one seminoma (2%), one liposarcoma (2%), and 3 cases of other malignancies (5%). Radiotherapy was performed with a median dose of 60 Gray (Gy) (range 40-67 Gy). AET was graded according to the Radiation Therapy Oncology Group (RTOG) criteria. The following parameters were analyzed with respect to associations with AET by univariate and multivariate analyses: age, gender, thoracic surgery before radiotherapy, concurrent chemotherapy, duration of radiotherapy, maximum esophageal dose, mean esophageal dose, and percentage of esophageal volume receiving from 10 Gy (V10) to 65 Gy (V65), in 5-Gy increments. 43 patients (70%) developed AET: 36 patients (59%) with AET of RTOG Grade 1, 7 patients (11%) with Grade 2, and no patients (0%) with Grade 3 or worse. On multivariate analysis, V35 > 30% was the most statistically significant factor associated with mild AET ( p = 0.013). Our findings provide a better understanding of the factors related to AET, and might be useful in designing a treatment plan to prevent severe esophageal toxicity.
Acute esophageal toxicity (AET) is known to be a significant dose-limiting toxicity (DLT) and one of the main complications of thoracic radiotherapy (TRT) given for lung cancer (Byhardt et al. 1998; Choy et al. 1999; Bruner et al. 2004) .
Previous researches reported the following dosimetric predictors for AET: the percentage of esophageal volume receiving > 45 Gy (V45), V50, V60; the length of the esophagus in the treatment field; the maximal esophageal point dose; hyper-fractionated radiotherapy; and the esophageal surface area receiving 55 Gy (A55) (Werner-Wasik et al. 2000; Hirota et al. 2001a; Singh et al. 2003; Bradley et al. 2004; Patel et al. 2004; Ahn et al. 2005; Kim et al. 2005) . Most of these predictors were related to AET Radiation Therapy Oncology Group (RTOG) criteria grade 2-3 or worse (Cox et al. 1995) . In contrast, our previous study indicated that V35 was a significant dosimetric predictor for AET of RTOG grade 1-2 (Takeda et al. 2005) .
Several authors have noted significant toxicity not only in lung cancer patients, but also in patients with other intra-thoracic malignancy (Hirota et al. 2001b; Perez and Early 2002; Chen et al. 2004 ). However, there have been few reports dealing with dosimetric parameters for AET in patients with intra-thoracic malignancies, including both lung cancer and other thoracic malignancy treated with TRT. Thus, in the present study, we evaluated clinical and dosimetric parameters associated with AET in intra-thoracic malignancy patients receiving TRT.
MATERIALS AND METHODS

Patient characteristics
Between February 2000 and April 2005, a total of 61 patients underwent TRT for lung cancer and other intra-thoracic malignancies at the National Hospital Organization Sendai Medical Center and Tohoku University Hospital in Sendai, Japan. All patients were hospitalized during treatment. To be included in this analysis, the 61 patients had to fulfill the following criteria: their charts, hospital computerized data, and radiotherapy datasets for calculation of dose-volume histograms (DVHs) had to be completed and readily available (Sailer 2000) (Fig. 1) ; they did not have pre-treatment dysphagia, anorexia, or ingestion difficulties; and they were not undergoing palliative treatment. Patient characteristics are shown in Table 1 . The study population included 44 men and 17 women with a median age of 68 years (range 26-88 years). The 43 lung cancer patients' histological types were reported as: adenocarcinoma, 16 patients (26%); squamous cell carcinoma, 13 patients (20%); large cell carcinoma, 3 patients (5%); spindle cell carcinoma, 1 patient (2%); small-cell carcinoma, 9 patients (15%); and not otherwise specified, 1 patient (2%). Four patients (6%) had stage I disease, 1 (2%) had stage II, 10 (17%) had stage IIIa, 11 (18%) had stage IIIb, 13 (21%) had stage IV, and 4 (6%) were treated for recurrent disease after surgery. The histology of the The dose-volume histogram (DVH) is one of the fundamental tools used in plan evaluation. At any point on the curve, one is reading the percentage of a volume that receives a dose greater than or equal to the specified dose (Do).
other diseases was: invasive thymoma, 4 patients (6%); thymic well-differentiated cancer, 6 patients (8%); thymic undifferentiated cancer, 1 patient (2%); heterotopic thyroid papillary carcinoma, 1 patient (2%); diffuse large B-cell type lymphoma, 1 patient (2%); relapsed Hodgkin disease, 1 patient (2%); seminoma, 1 patient (2%); liposarcoma, 1 patient (2%); undifferentiated cancer, 1 patient (2%); and metastatic adenocarcinoma, 1 patient (2%). According to the thymoma staging system of Masaoka et al. (1981) , 1 thymoma patient (2%) had stage II, 1 (2%) had stage III, and 2 (3%) had stage IV. Fifteen patients (25%) underwent thoracic surgery before TRT: postoperative prophylactic TRT for lung cancer, 1 patient (2%); invasive thymoma, 3 patients (5%); thymic welldifferentiated cancer, 4 patients (6%); heterotopic thyroid papillary carcinoma, 1 patient (2%); seminoma, 1 patient (2%); liposarcoma, 1 patient (2%); and postoperative recurrent lung cancer, 4 patients (6%). We did not include esophageal cancer patients in this study, due to difficulties in evaluating AET in these patients based on clinical and dosimetric analyses. It is very difficult to contour when normal tissue must be distinguished from the malignant portion on computed tomograpy (CT) images in esophageal cancer patients. Furthermore, clinically it is often difficult to clearly determine whether symptoms are due to esophageal cancer or AET. A total of 41 patients (67%) were treated with concurrent chemoradiotherapy. The regimens of concurrent chemotherapy are summarized in Table 2 . Carboplatin was administered at a dose equal to an area under the plasma concentration-time curve of 5-6 every 4 weeks for 2-3 consecutive cycles. Cisplatin (45-80 mg/m 2 ) was Invasive thymoma 4 (6) Thymic well-differentiated cancer 6 (8) Thymic undifferentiated cancer 1 (2) Heterotopic thyroid cancer 1 (2) Diffuse large B-cell lymphoma 1 (2) Hodgkin disease 1 (2) Seminoma 1 (2) Liposarcoma 1 (2) Undifferentiated cancer 1 (2) Metastatic adenocarcinoma 1 (2) given every 3-4 weeks for 3 consecutive cycles. The dose and schedule for the administration of combined agents during the radiotherapy period were: paclitaxel 
Treatment planning and treatment
CT-based treatment planning was done in all patients with immobilization devices. Radio-opaque markers were placed on the patient's skin, and the immobilization device was used to assist in positioning.
The treatment planning for lung cancer patients was based on gross tumor volume (GTV) that included all the tumors and abnormally enlarged regional lymph nodes greater than 1 cm in diameter seen on CT images (International Commission on Radiation Units and Measurements 1993; Clifford et al. 2002) (Fig. 2) . Clinical target volume (CTV) encompassed the GTV, as well as the mediastinal and ipsilateral pulmonary hilar lymph nodes that were regarded as having potential microscopic disease. Planning target volume (PTV) 1 included the CTV and a 1-1.5 cm margin. PTV2 involved the GTV and a 1 cm margin. Radiation was given through the anteroposterior-posteroanterior (AP-PA) portals for PTV1 up to 39.6-40 Gy, followed by offspinal cord oblique portals for PTV2 in a sequential manner. The treatment planning for patients with other diseases was based on GTV that included all the tumors or residual tumors after surgical resection. CTV included the GTV and a 1-1.5 cm margin, or preoperatively all of the tumors and a 1-2 cm margin. PTV encompassed the CTV and a respiratory movement margin. TRT was directed through the AP-PA portals followed by offspinal cord oblique portals for PTV sequentially, or twowedge portals (right and left anterior oblique) for PTV. TRT was delivered by linear accelerators with 4 MV, 6 MV, or 10 MV X-rays using single daily fractions of either 1.8 Gy or 2.0 Gy. The dose to which the spinal cord was exposed was kept below 45 Gy. The median prescription dose to the isocenter was 60 Gy (range 40-67 Gy). Dose calculations were performed to correct for lung in-homogeneity, using superposition algorithm. The median corrected dose for all patients was 60 Gy (range 40-68 Gy).
Follow-up and evaluation of AET
The follow-up period for all patients was from 2 to 37 months, with a median of 8 months. At least once a week during the course of TRT, patients were evaluated and treated by a radiation oncologist for any complaints. After completion of treatment, patients were followed-up at one-month intervals during the first year and then every 3 to 6 months by their physicians. AET was graded according to RTOG criteria (Cox et al. 1995) (Table 3) . The data used to grade the esophagitis reflected the worst grade of toxicity experienced by the patients.
Acquisition of dosimetric data and statistical analysis
The patients' treatment plans were analyzed retrospectively so as to determine the significant factors that could have been involved in causing AET. Our institutional committee did not require ethical approval for this retrospective study. The external surface of the esophagus was contoured uniformly on each 5 mm axial image of the planning CT scan from the level of the lower end of the cricoid cartilage to the gastroesophageal junction by one of the authors. DVHs and dose distributions for the esophagus were calculated. We analyzed the following dosimetric parameters: maximum esophageal dose (Dmax); mean esophageal dose (Dmean); and V10 to V65 in 5-Gy dose increments. Means, medians, and ranges of these parameters are shown in Table 4 . Furthermore, we examined the correlation between AET and the following factors: age, gender, thoracic surgery before TRT, concurrent chemotherapy, chemotherapeutic agents, and overall TRT duration. These parameters were analyzed with respect to their relationship with Grade 1 or greater esophagitis using Fisher's exact test (two-tailed), chi-square test (two-tailed), and Spearman rank correlation analysis (two-tailed). For multivariate analysis, the stepwise procedure was performed using a logistic regression method containing all variables that achieved univariate statistical significance. Statistical analyses were performed using SPSS (version 11.0 for Windows). Values of p < 0.05 were considered statistically significant. 
RESULTS
Forty-three of 61 patients (70%) developed AET. The worst AET RTOG grades experienced by the patients were: Grade 1, 36 patients (59%); Grade 2, 7 patients (11%); Grade 3 or worse, 0 patients (0%). In this study, all cases of AET developed during the TRT period, and the patients recovered from AET immediately after TRT completion. All patients had completed TRT without pause due to AET. None of the patients died within 1 month of TRT completion, and none developed severe dehydration.
There were no significant correlations with the following factors: age, p = 0.868, correlation coefficient = −0.022 (Spearman's rank correlation); gender, p = 0.229 (Fisher's exact test); thoracic surgery before TRT, p = 0.34 (Fisher's exact test); concurrent chemotherapy, p = 0.242 (Fisher's exact test); chemotherapeutic agents, p = 0.259 (Pearson's chi-square test); and overall TRT duration, p = 0.244, correlation coefficient = 0.151 (Spearman's rank correlation). Table 5 shows the results of Spearman's rank correlation for Dmean and V10-V55 to predict AET. On logistic regression analysis, the most statistically significant predictor of AET is V35 ( p = 0.020). AET developed in 18 of 32 patients (56.3%) with V35 30% and in 25 of 29 patients (86.2%) with V35 > 30%, p = 0.013 (Fisher's exact test, two tail). AET developed in 6 of 14 patients (42.9%) with V35 15% and in 37 of 47 patients (78.7%) with V35 > 15%, p = 0.018 (Fisher's exact test, two tail). Furthermore, AET developed in 17 of 44 patients (38.6%) with V35 40% and in 16 of 17 patients (94.1%) with V35 > 40%, p = 0.013 (Fisher's exact test, two tail). On logistic regression analysis, V35 > 30% was the most significant factor ( p = 0.013).
DISCUSSION
Previous studies have identified several clinical and dosimetric factors that are related to radiation-induced esophageal toxicity (ET) in patients with lung cancer (Werner-Wasik et al. 2000; Hirota et al. 2001a; Singh et al. 2003; Bradley et al. 2004; Patel et al. 2004; Ahn et al. 2005; Kim et al. 2005; Takeda et al. 2005) (Table 6 ). However, there have been few studies that have examined these factors for ET in patients with other thoracic malignancies, though several authors have reported on ET in patients with intra-thoracic malignancies (Hirota et al. 2001b; Perez et al. 2002; Chen et al. 2004 ). According to Chen et al. (2004) , Grade 1-2 esophagitis was one of the most common side effects in concurrent chemoradiotherapy for thymic carcinoma. AET occurs not only in lung cancer patients, but also in patients with other intra-thoracic malignancies patients receiving TRT. Therefore, in the present study, we investigated the clinical and dosimetric factors of AET in intra-thoracic malignancies including both lung cancer and other intra-thoracic malignancies.
As shown in Table 6 , although most of previous studies indicated parameters of AET of RTOG grade 2 or worse, there are few reports about AET of RTOG grade 2 or less. However, according to previous publications, the incidence of AET of RTOG grade 1 in lung cancer patients is higher Ahn et al. (2005) reported 138 patients with AET of RTOG Grade 1 in their 254 patient series. Therefore, we believe that our result about AET of RTOG grade 2 or less has significance, though it may not be fatal. In the present study, we did not observe any cases of severe AET of RTOG grade 3 or worse, as was the case in our prior report (Takeda et al. 2005) . One reason for this may have been that our prescribed doses are lower than those in other studies (Singh et al. 2003; Bradley et al. 2004; Patel et al. 2004; Ahn et al. 2005) , or that our study did not use TRT with BID fractionation (Werner-Wasik et al. 2000; Ahn et al. 2005) . Another reason may be that concurrent chemotherapy was given consistently in other studies and, therefore, resulted in higher toxicity (Hirota et al. 2001a; Kim et al. 2005) . Although previous authors have noted significant correlations between concurrent chemotherapy and AET in lung cancer treatment (Werner-Wasik et al. 2000; Singh et al. 2003; Bradley et al. 2004; Kim et al. 2005 ), we did not find a statistically significant relationship between AET and chemotherapy, probably due to the in- homogeneity of our patients' disease and their treatments, which included various chemotherapeutic regimens, thus lessening the significance of any correlation. Furthermore, as this was a retrospective study, the chemotherapy was not randomly assigned.
In conclusion, the present study has demonstrated that V10-V55 and Dmean are significant parameters associated with mild AET. V35 > 30% appears to be the most critical factor in patients with intra-thoracic malignancies in TRT. Our findings provide new information about AET, and might be useful in designing a treatment plan to prevent severer esophageal toxicity.
